{"id":"NCT00605267","sponsor":"AstraZeneca","briefTitle":"Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment","officialTitle":"Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-11","completion":"2010-12","firstPosted":"2008-01-31","resultsPosted":"2012-09-06","lastUpdate":"2012-09-06"},"enrollment":197,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Tamoxifen","otherNames":["NOLVADEX"]},{"type":"DRUG","name":"Anastrazole (Arimidex)","otherNames":["ARIMIDEX","ZD1033"]},{"type":"DRUG","name":"Goserelin acetate (Zoladex)","otherNames":["ZOLADEX"]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this multi-centre, randomised, double-blind, parallel-group study is to compare efficacy and safety between anastrozole and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for premenopausal breast cancer patients","primaryOutcome":{"measure":"Best Overall Response Rate (BORR) (Calliper)","timeFrame":"24 weeks","effectByArm":[{"arm":"Anastrozole 1 mg","deltaMin":70.4,"sd":null},{"arm":"Tamoxifen 20 mg","deltaMin":50.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":["22265697"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":98},"commonTop":["Hot Flush","Arthralgia","Nasopharyngitis","Headache","Musculoskeletal Stiffness"]}}